uniQure (NASDAQ:QURE) Shares Gap Down – Should You Sell?

Shares of uniQure N.V. (NASDAQ:QURE) gapped down before the market opened on Thursday . The stock had previously closed at $24.87, but opened at $20.90. uniQure shares last traded at $18.5670, with a volume of 4,022,746 shares trading hands.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Neutral Sentiment: Wolfe Research initiated coverage of uniQure with a “peer perform” rating — an analyst view that is not a clear bullish catalyst and may be seen as neutral to slightly negative given the company’s recent volatility. Wolfe Research story
• Neutral Sentiment: Analyst roundup coverage (5 analysts assessed uniQure) provides additional research flow but no clear consensus upgrade that would offset recent legal and regulatory pressure. Analyst summary
• Negative Sentiment: A securities‑fraud class action has been filed covering purchases between Sept. 24, 2025 and Oct. 31, 2025; multiple national plaintiff firms (including Berger Montague, Kessler Topaz, Pomerantz, Rosen, Levi & Korsinsky, Faruqi & Faruqi, Bragar Eagel & Squire and others) are soliciting lead‑plaintiff applications with an April 13, 2026 deadline — increasing legal risk, potential discovery/costs, and short‑term selling pressure. Berger Montague filing
• Negative Sentiment: Coverage and alerts from many plaintiff firms and services (ClaimsFiler, Bernstein Liebhard, Kahn Swick & Foti, etc.) amplify the publicity around the suit and the April 13 lead‑plaintiff deadline — typically a near‑term headwind for stocks as institutional and retail holders react. Bernstein Liebhard alert
• Negative Sentiment: Media reporting ties the class action to an FDA approval delay and an earlier ~49% stock drop — an allegation that, if litigated, can raise uncertainty about management disclosures and regulatory timing. GazetteXtra report

Analysts Set New Price Targets

A number of research firms recently issued reports on QURE. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of uniQure in a report on Tuesday, February 10th. William Blair reaffirmed a “market perform” rating on shares of uniQure in a report on Tuesday, November 11th. Wells Fargo & Company lowered their target price on uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, November 12th. Wolfe Research assumed coverage on uniQure in a research note on Monday. They set a “peer perform” rating on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of uniQure in a report on Wednesday, January 14th. Ten equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $58.33.

uniQure Stock Performance

The stock’s 50-day moving average is $23.76 and its 200 day moving average is $29.67. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. The firm has a market cap of $1.09 billion, a P/E ratio of -3.99 and a beta of 0.66.

Insider Activity at uniQure

In other uniQure news, Director Jack Kaye sold 6,390 shares of uniQure stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the transaction, the director owned 20,439 shares of the company’s stock, valued at approximately $557,575.92. The trade was a 23.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Robert Gut sold 25,613 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the sale, the director directly owned 32,342 shares in the company, valued at $796,260.04. This represents a 44.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 4.79% of the company’s stock.

Institutional Investors Weigh In On uniQure

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Private Trust Co. NA bought a new position in shares of uniQure in the 3rd quarter valued at about $28,000. Jones Financial Companies Lllp raised its position in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC acquired a new position in shares of uniQure during the 3rd quarter worth about $50,000. Torren Management LLC bought a new position in uniQure during the fourth quarter worth about $28,000. Finally, FNY Investment Advisers LLC lifted its position in shares of uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 718 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.